Study on How Dupilumab Affects Anxiety and Depression in Moderate-to-Severe Atopic Dermatitis Patients in Gulf Countries

What this Trial Is About

Researchers are studying the effects of dupilumab treatment on mental health, specifically anxiety and depression symptoms, as well as quality of life in patients with moderate-to-severe atopic dermatitis AD. The study focuses on patients already receiving dupilumab, aiming to observe how this treatment impacts their psychological well-being and life quality over time. Participants will be observed during a 6-month period while continuing their dupilumab therapy as prescribed by their doctors in real-world clinical settings. The study does not administer any treatments but monitors patients who start dupilumab within 30 days before enrollment. The enrollment period for the study will last about 9 months. Throughout the study, participants will complete assessments measuring anxiety and depression levels using the Hospital Anxiety and Depression Scale HADS and quality of life via tools like the Patient-Oriented Eczema Measure POEM and Dermatology Life Quality Index DLQI. Researchers will evaluate changes from baseline to week 24 in these scores and monitor professional and psychological impacts. The study aims to better understand the mental health outcomes of patients receiving dupilumab over six months.

The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis